Kypha, a medical diagnostics company with an innovative testing platform for precision monitoring of immune system activity to improve patient care and advance immune-targeted drug development, has secured $4 million in Series A funding led by Arsenal Capital Management.
| ST LOUIS, /PRNewswire/ -- Kypha, a medical diagnostics company with an innovative testing platform for precision monitoring of immune system activity to improve patient care and advance immune-targeted drug development, has secured $4 million in Series A funding led by Arsenal Capital Management. This is Kypha’s third capital investment led by ACM, a St. Louis-based venture capital firm focused on emerging growth companies across several industries, including healthcare.
The Series A funding is being used to complete integration and expand manufacturing capacity of recently acquired Biosensia and its ISO 13485-certified facilities in Dublin, Ireland; to support commercial launch of additional Kypha tests; and to expand partnerships with leading-edge pharmaceutical companies advancing several promising new blockbuster therapies targeting complement, a central arm of the immune system. Kypha’s technology is the only platform that can enable reliable complement testing at scale from home health to clinical laboratory, to support precision immune monitoring as standard of care in a growing multi-billion dollar complement drug and immunotherapy marketplace. More precise and frequent monitoring of complement and immune activity can facilitate quicker and more accurate treatment decisions – reducing costly misdiagnoses, and ultimately improving outcomes for millions of patients with immune system disorders. Precision immune monitoring impacts the entire care continuum across a diverse range of conditions including autoimmune disorders, inflammatory disease, and cancer. Tremendous unmet need in these areas, coupled with the growth of immune-targeted therapies, is driving the demand for and impact of complement testing - most of which is not currently reliable, timely, or scalable. Current testing is complex, with inconsistent results often taking weeks. Kypha’s platform overcomes technical obstacles and makes consistently accurate testing widely available with actionable, cost-effective results delivered in minutes. “The past year has been transformative for Kypha with the acquisition of Biosensia and explosive growth in the complement therapeutics market. Building on 8 years of technical innovation and deep understanding of clinical workflows, we are excited to secure this additional funding in support of commercial and strategic partnering goals that will deliver pivotal companion diagnostics and immune monitoring solutions to drug developers, patients, providers and payers. Together we can ensure earlier detection, accurate and cost-effective diagnosis, faster treatment optimization and improved management of many lifelong immune-mediated conditions,” stated Chad Stiening, CEO Kypha. Pete Reinecke, Managing Director ACM stated, “We remain very positive about the opportunity Kypha has to bring its innovative testing platform to the market. Bringing new technologies to the healthcare market is always challenging; the Kypha team has worked extremely hard in 2018 and positioned the Company for great success. We look forward to working alongside them in 2019.” For more information on Kypha and to see the passion that’s driving this company, visit kypha.net About Kypha: About Biosensia:
SOURCE Kypha |
View original content to download multimedia:
